The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Unravelling drug resistance and sensitization
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, provides a summary of his EMN presentation, which focused on unraveling drug resistance and sensitization to proteasome inhibitors using genome-wide CRISPR-Cas9 knockout screening. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.
